Tuesday, February 1, 2011

Orexigen (OREX) - FDA rejects Contrave, sending Orexigen back to the drawing board

~~~BREAKING NEWS~~~

FDA rejects Orexigen's Contrave


Orexigen's stock (OREX) crashed this morning as FDA rejected it's 'hopeful' diet drug, Contrave.  The agency is worried about the heart risks associated with the drug and has requested for a trial with a large number of patients and longer duration.  Enough said by the chart above and congrats to those anticipating the fall of OREX!

No comments:

Post a Comment